Gopi MBA - Larimar Therapeutics Chief Officer
| LRMR Stock | USD 6.33 0.31 4.67% |
Executive
Gopi MBA is Chief Officer of Larimar Therapeutics
| Age | 53 |
| Address | Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004 |
| Phone | 844 511 9056 |
| Web | https://www.larimartx.com |
Larimar Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2855) % which means that it has lost $0.2855 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.445) %, meaning that it created substantial loss on money invested by shareholders. Larimar Therapeutics' management efficiency ratios could be used to measure how well Larimar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to grow to -0.46. At this time, Larimar Therapeutics' Non Currrent Assets Other are relatively stable compared to the past year. As of 11/29/2024, Other Assets is likely to grow to about 2.4 M, while Non Current Assets Total are likely to drop slightly above 3.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ellie MD | Centessa Pharmaceuticals PLC | N/A | |
| Paul MBA | Vaxcyte | 63 | |
| Andrew MD | Merus BV | 58 | |
| Barbara Leyman | Sutro Biopharma | N/A | |
| Katie Hogan | Alector | N/A | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
| Regina Cheng | Sutro Biopharma | N/A | |
| Elvia Cowan | Vaxcyte | 51 | |
| Kathleen Farren | Merus BV | N/A | |
| Zung To | Kezar Life Sciences | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Kevin McManus | Syndax Pharmaceuticals | 55 | |
| Venkatesh Srinivasan | Sutro Biopharma | 62 | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Pattie Chiang | Kezar Life Sciences | N/A | |
| Arun MD | Cabaletta Bio | 34 | |
| Michael JD | Immuneering Corp | 37 | |
| MRCP MD | Coherus BioSciences | 55 | |
| Ashley PharmD | Merus BV | N/A | |
| Harp MBA | Vaxcyte | 51 | |
| Tamara LLM | Spero Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 |
Larimar Therapeutics Leadership Team
Elected by the shareholders, the Larimar Therapeutics' board of directors comprises two types of representatives: Larimar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Larimar. The board's role is to monitor Larimar Therapeutics' management team and ensure that shareholders' interests are well served. Larimar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Larimar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gopi MBA, Chief Officer | ||
| DO Sr, Chief Officer | ||
| Francis Conway, VP Controller | ||
| Carole MD, President CEO | ||
| Sr DO, Chief Officer | ||
| Michael CPA, Secretary CFO | ||
| John Berman, Vice Administration | ||
| Jennifer Johansson, Vice Compliance | ||
| Nancy Ruiz, Chief Officer | ||
| Francis CPA, VP Controller |
Larimar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Larimar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 225.33 M | ||||
| Shares Outstanding | 63.81 M | ||||
| Shares Owned By Insiders | 1.45 % | ||||
| Shares Owned By Institutions | 98.55 % | ||||
| Number Of Shares Shorted | 3.31 M | ||||
| Price To Book | 2.14 X | ||||
| EBITDA | (41.45 M) | ||||
| Net Income | (36.95 M) |
Pair Trading with Larimar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.